FindTrial
Sign In

Evaluation and demonstration study on the application of AI Epic Co-Ablation System for neoplasms of the genitourinary system

Evaluation and demonstration study on the application of AI Epic Co-Ablation System for tumors from urogenital system

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080897
Enrollment
Unknown
Registered
2024-02-18
Start date
2024-02-19
Completion date
Unknown
Last updated
2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neoplasms of the genitourinary system

Interventions

Ablation:Co-Ablation

Sponsors

Beijing Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 100 Years

Inclusion criteria

Inclusion criteria: (1) At least 18 years old; (2) Gender unlimited; (3) Patients who have been clinically or pathologically diagnosed as solid tumors of the genitourinary system and have received percutaneous puncture combined with Co-Ablation treatment after pathological or imaging evaluation.

Exclusion criteria

Exclusion criteria: (1) The hospital information system (HIS) and image archiving and communication system (PACS) cannot retrieve or provide patient baseline and treatment-related information.

Design outcomes

Primary

MeasureTime frame
Technical effectiveness (for benign tumor);Local effective control rate (for maliganancy);—

Secondary

MeasureTime frame
Technical success rate;12-month local control rate;Quality of life;Local effective rate every 3 months after surgery;Local recurrence rate;progression-free survival;cancer-specific survival;overall survival;—

Countries

China

Contacts

Public ContactLi Xiaoguang

Beijing Hospital

lixiaoguang4678@bjhmoh.cn+86 136 8338 3783

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026